CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cue Biopharma, Inc., an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune diseases, today announced that Mary Simcox, Ph.D., will serve as the Vice President of Translational Biology. Dr. Simcox joins the Cue Biopharma leadership team with more than 20 years of experience in cancer cell biology as well as pharmaceutical and antibody drug discovery, most recently as Vice President of Biology at Tarveda Therapeutics.

“Mary’s impressive track record, especially her work advancing various antibody and small molecule compounds into the clinic will provide additional experienced leadership to draw from as we continue to further build and advance our platform and portfolio of biologics for targeted immune modulation,” said Daniel Passeri, M.Sc., J.D., President and Chief Executive Officer of Cue Biopharma. “Throughout her career, Mary has developed deep competencies across a wide range of interdependent areas, including drug target discovery, translational medicine, mechanisms of drug resistance and cancer cell biology. Her experience and professionalism will enhance our capabilities and prove extremely valuable for guiding us as we continue to advance CUE-101 into the clinic and further build our pipeline.”

“I am thrilled to be joining the team at Cue Biopharma,” said Dr. Simcox. “The company’s novel approach to selective immune modulation is very promising and has the potential to be transformational. I look forward to leading the translational biology group as we move towards the clinic.”

Before joining Cue, Dr. Simcox held various leadership positions at Tarveda Therapeutics, FORMA Therapeutics and Roche. Prior to Tarveda, she was Director of Biology at FORMA, where she oversaw the protein homeostasis target project portfolio. In this role, she led the discovery efforts to characterize novel pathway biology to discover and characterize potent and selective small molecule inhibitors to progress toward clinical development. Prior to FORMA, she held several leadership roles at Roche, where she led several small molecule and antibody projects into clinical development, worked to understand the mechanisms of resistance to Zelboraf® and Avastin®, led translational work on an anti-TWEAK antibody, and led discovery programs for the development of small molecule inhibitors of VEGFR2 and CDK2. Her undergraduate and doctoral work were completed at the University of California at Davis, where she earned a B.S. in Biochemistry and a Ph.D. in Nutrition.

About Cue Biopharma

Immune Responses, On Cue. Cue Biopharma™ is an immunotherapy company developing biologics engineered to selectively communicate with disease-relevant T cell subsets to treat cancer and autoimmune disease. Cue Biopharma biologics have the potential to be highly effective as monotherapies as well as synergistic with existing checkpoint inhibitors, while reducing collateral toxicities often seen with less selective immunotherapies. Through this platform approach, Cue Biopharma has developed a promising pipeline with its lead candidate currently approaching the clinic. Headquartered in Kendall Square, Cambridge, MA, the Company is led by a strong, experienced management team and scientific and clinical advisory board with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.

For more information, visit www.cuebio.com.